3. Custódio G, Parise GA, Kiesel Filho N, et al. Impact of
Neonatal Screening and Surveillance for the TP53 R337H Mutation on Early
Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013; 31:
2619-2626.
4. Allolio B, Fassnacht M. Adrenocortical carcinoma, In: Grossman, A.P.
Endocrinology Adult and pediatric, The adrenal gland. sixth ed.
Philadelphia: Elsevier; 2010, pp. e168.
5. Mauclère-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane
strategy in adrenocortical carcinoma: prospective analysis of plasma
mitotane measurement during the first 3 months of follow-up. Eur J
Endocrinol 2012; 166: 261–268. https://doi.org/10.1530/EJE-11-0557
6. Zancanella P, Pianovski MA, Oliveira BH, et al. Mitotane Associated
with cisplatin, etoposide, and doxorubicin in advanced childhood
adrenocortical carcinoma. J Pediatr Hematol Oncol 2006; 28: 513–524.
https://doi.org/10.1097/01.mph.0000212965.52759.1c
7. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with
etoposide, doxorubicin, and cisplatin in the treatment of advanced
adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Cancer 1998; 83: 2194-2000.
8. Pereira RM, Michalkiewicz E, Sandrini F, et al. Childhood
Adrenocortical Tumors: A Review. Arq Bras Endocrinol Metabol 2004; 48:
651-658.
9. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane
treatment achieves the therapeutic range with manageable side effects in
patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85:
2234–2238. https://doi.org/10.1210/jcem.85.6.6619
10. Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation
of mitotane toxicity in adrenocortical cancer patients treated
adjuvantly. Endocr Relat Cancer 2008; 15: 1043–1053.
https://doi.org/10.1677/ERC-08-0103
11. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic)
and hepatic damage produced in dogs by feeding
2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE). Arch Pathol
(Chic) 1949; 48: 387–394.
12. Nichols J, Green HD. Effect of DDD Treatment on Metabolic Response
of Dogs to ACTH Injection. Am J Physiol 1954; 176:
374–376. https://doi.org/10.1152/ajplegacy.1954.176.3.374
13. Bergenstal DM, Lipsett MB, Moy RH, et al. Regression of adrenal
cancer and suppression of adrenal function in men by o,p′-DDD. Trans
Assoc Am Physicians 1959; 72: 341.
https://doi.org/10.1016/B978-1-4832-2866-2.50035-0
14. Waszut U, Szyszka P, Dworakowska D. Understanding mitotane mode of
action. J Physiol Pharmacol 2017; 68: 13–26.
15. Megerle F, Kroiss M, Hahner S, et al. Advanced Adrenocortical
Carcinoma – What to do when First-Line Therapy Fails?. Exp Clin
Endocrinol Diabetes 2018; 127: 109–116.
https://doi.org/10.1055/a-0715-1946
16.
Puglisi
S,
Calabrese
A, Basile V, et al. New perspectives for mitotane treatment of
adrenocortical carcinoma. Best Pract Res Clin Endocrinol & Metab 2020;
101415.
17. Tang Y, Liu Z, Zou Z, et al. Benefits of Adjuvant Mitotane after
Resection of Adrenocortical Carcinoma: A Systematic Review and
Meta-Analysis. Biomed Res Int 2018; 9362108.
https://doi.org/10.1155/2018/9362108
18.
Fassnacht
M, Terzolo
M,
Allolio
B, et
al. FIRM-ACT
Study Group, Combination chemotherapy in advanced adrenocortical
carcinoma. N Engl J Med 2012; 366: 189-197.
19. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination
chemotherapy and surgical resection for the treatment of metastatic
adrenocortical carcinoma: continuous infusion doxorubicin, vincristine,
and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer
2002; 94: 2333-2343.
20. Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with
previously treated metastatic adrenocortical carcinoma: Phase 1b results
from the JAVELIN solid tumor trial. J Immunother Cancer 2018; 6: 111.
21. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and
cisplatin plus mitotane in the treatment of advanced adrenocortical
carcinoma: A large prospective phase II trial. Endocr Relat Cancer 2005;
12: 657-666.
22. Bukowski RM, Wolfe M, Levine HS, et al. Phase II Trial of Mitotane
and Cisplatin in Patients With Adrenal Carcinoma: A Southwest Oncology
Group Study. J Clin Oncol 1993; 11: 161-165.
23. Williamson SK, Lew D, Miller GJ, et al. Phase II Evaluation of
Cisplatin and Etoposide Followed by Mitotane at Disease Progression in
Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma: a
Southwest Oncology Group Study. Cancer 2000; 88: 1159-1165.
24. Gold B, Brunk G. A mechanistic study of the metabolism of
1,1-dichloro-2,2-bis(p-chlorophenyl)ethane (DDD) to
2,2-bis(p-chlorophenyl)acetic acid (DDA). Biochem Pharmacol 1984; 33:
979–982. https://doi.org/10.1016/0006-2952(84)90503-3
25. Doghman M, Lalli E. Lack of long-lasting effects of mitotane
adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Mol Cell Endocrinol 2013; 381: 66–69.
https://doi.org/10.1016/j.mce.2013.07.023
26. Moolenaar AJ, van Slooten H, van Seters AP, et al. Blood Levels of
o,p′-DDD Following Administration in Various Vehicles After a Single
Dose and During Long-term Treatment. Cancer Chemother Pharmacol 1981; 7:
51–54. https://doi.org/10.1007/bf00258213
27. D’Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6
polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics
2013; 23: 293–300. https://doi.org/10.1097/FPC.0b013e3283606cb2